Payment overview · 2025
General Payments
$399.18
19 reported records · 11 companies
Healthcare provider profile · identity verified
Amber H Driskell, MD
Allopathic & Osteopathic Physicians|Internal Medicine · AUSTELL, GA · NPI 1821158759
Verified facts
What the public records show
CMS Open Payments records show Amber H Driskell, MD received $399.18 in general payments during 2025 across 19 reported records.
Novo Nordisk Inc accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 173 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $80.68 | 20.2% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $66.32 | 16.6% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $51.29 | 12.8% | 2 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $41.72 | 10.4% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.60 | 9.2% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.04 | 6.0% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.01 | 6.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.87 | 5.2% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $18.55 | 4.7% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.32 | 4.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.78 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $399.18 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $66.32 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $51.29 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $42.22 | 2 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $41.72 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.46 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.60 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $24.04 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.01 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.32 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $18.55 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.32 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.85 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 119 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 114 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
82 | 21 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
114 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
173 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 634 | 184 |
| Levothyroxine Sodium | Levothyroxine Sodium | 580 | 155 |
| Atorvastatin Calcium | Atorvastatin Calcium | 570 | 184 |
| Losartan Potassium | Losartan Potassium | 555 | 173 |
| Pantoprazole Sodium | Pantoprazole Sodium | 380 | 106 |
| Omeprazole | Omeprazole | 296 | 92 |
| Gabapentin | Gabapentin | 294 | 85 |
| Simvastatin | Simvastatin | 258 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 238 | 78 |
| Metformin Hcl | Metformin Hcl | 235 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 215 | 71 |
| Trazodone Hcl | Trazodone Hcl | 205 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 199 | 59 |
| Lisinopril | Lisinopril | 199 | 65 |
| Tramadol Hcl | Tramadol Hcl | 188 | 39 |
| Sertraline Hcl | Sertraline Hcl | 187 | 61 |
| Eliquis | Apixaban | 173 | 33 |
| Montelukast Sodium | Montelukast Sodium | 172 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 146 | 45 |
| Metformin Hcl Er | Metformin Hcl | 142 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 39 |
| Potassium Chloride | Potassium Chloride | 129 | 38 |
| Jardiance | Empagliflozin | 119 | 30 |
| Ozempic | Semaglutide | 114 | 24 |
| Carvedilol | Carvedilol | 108 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 52 |
| Meloxicam | Meloxicam | 104 | 34 |
| Glimepiride | Glimepiride | 102 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 97 | 43 |
| Allopurinol | Allopurinol | 96 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 30 |
| Famotidine | Famotidine | 94 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 93 | 27 |
| Mirtazapine | Mirtazapine | 91 | 28 |
| Synthroid | Levothyroxine Sodium | 82 | 21 |
| Alendronate Sodium | Alendronate Sodium | 81 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 81 | 19 |
| Furosemide | Furosemide | 79 | 28 |
| Nifedipine Er | Nifedipine | 79 | 24 |
| Alprazolam | Alprazolam | 77 | 17 |
| Januvia | Sitagliptin Phosphate | 77 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 20 |
| Pregabalin | Pregabalin | 76 | 18 |
| Valsartan | Valsartan | 74 | 23 |
| Ezetimibe | Ezetimibe | 72 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 71 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 71 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 70 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 65 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 17 |
| Memantine Hcl | Memantine Hcl | 64 | 17 |
| Atenolol | Atenolol | 63 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | 16 |
| Clonazepam | Clonazepam | 59 | 14 |
| Prednisone | Prednisone | 59 | 43 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 55 | 22 |
| Rybelsus | Semaglutide | 55 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 29 |
| Nystatin | Nystatin | 52 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 50 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 50 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 23 |
| Fluconazole | Fluconazole | 48 | 31 |
| Baclofen | Baclofen | 46 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 13 |
| Donepezil Hcl | Donepezil Hcl | 44 | 13 |
| Lovastatin | Lovastatin | 44 | 13 |
| Sucralfate | Sucralfate | 43 | 17 |
| Valacyclovir | Valacyclovir Hcl | 42 | 21 |
| Glipizide | Glipizide | 41 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 40 | 15 |
| Myrbetriq | Mirabegron | 40 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 38 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 35 | 11 |
| Cefuroxime | Cefuroxime Axetil | 35 | 29 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 31 |
| Glipizide Er | Glipizide | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | 14 |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 13 |
| Finasteride | Finasteride | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | 16 |
| Prolia | Denosumab | 26 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Estradiol | Estradiol | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 16 |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 14 | suppressed |
| Epinephrine | Epinephrine | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $399.18 · 19 records | Novo Nordisk Inc | Dexcom G6 Transmitter, FREESTYLE LIBRE 3, INSPIRE, JARDIANCE, LEQEMBI, NEFFY, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, UBRELVY, Veozah, Wegovy, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error